CD19 and neoplasm: Pre-sensitization of CD19+ tumor cells prior to anti-CD19 CAR T cell therapy with the Bcl-2 inhibitor venetoclax or with the Mcl-1 inhibitor S63845 led to higher target antigen expression and an upregulation of pro-apoptotic proteins in tumor cells, which consequently improved the killing and proliferation of CAR T cells [110].